BridgeBio Pharma (BBIO) Cash from Operations Growth (3y) (2021 - 2026)
BridgeBio Pharma (BBIO) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 34.32% |
| 10 | BridgeBio Pharma | 16.60 Bn | 15.66 Bn | 184.58 Mn | -10.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.98% |
| Dec 31, 2025 | 15.42% |
| Sep 30, 2025 | 6.76% |
| Jun 30, 2025 | -38.37% |
| Mar 31, 2025 | -7.44% |
| Dec 31, 2024 | -13.41% |
| Sep 30, 2024 | -14.10% |
| Jun 30, 2024 | 41.19% |
| Mar 31, 2024 | -13.35% |
| Dec 31, 2023 | -9.05% |
| Sep 30, 2023 | -3.32% |
| Jun 30, 2023 | -8.87% |
| Mar 31, 2023 | -19.81% |
| Dec 31, 2022 | -6.96% |
| Sep 30, 2022 | -39.31% |
| Jun 30, 2022 | 23.58% |
| Mar 31, 2022 | -39.53% |
| Dec 31, 2021 | -42.35% |
| Sep 30, 2021 | -46.93% |